ImmunoGen, Inc.
(NASDAQ : IMGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 17.06%127.810.0%$2003.07m
BIIBBiogen, Inc. 0.71%243.461.7%$667.89m
AMGNAmgen, Inc. 2.24%225.251.3%$582.82m
GILDGilead Sciences, Inc. 0.59%59.851.0%$532.70m
VRTXVertex Pharmaceuticals, Inc. 3.16%225.001.9%$484.47m
REGNRegeneron Pharmaceuticals, Inc. 1.35%515.162.7%$475.76m
BNTXBioNTech SE 4.02%109.180.0%$472.74m
NVAXNovavax, Inc. 24.84%128.0992.9%$464.99m
ILMNIllumina, Inc. 4.42%317.413.5%$398.01m
MGENMiragen Therapeutics, Inc. 2.25%16.580.7%$273.18m
APVOAptevo Therapeutics, Inc. 0.88%44.2018.3%$232.61m
EXASEXACT Sciences Corp. 2.98%119.3219.6%$202.61m
SGENSeagen Inc. 2.19%169.085.8%$182.00m
SRRKScholar Rock Holding Corp. 3.85%46.420.0%$171.89m
ALXNAlexion Pharmaceuticals, Inc. 0.64%123.712.0%$165.71m

Company Profile

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.